1-6 of 6
Hideyuki Honda
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1/2 Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Venetoclax in Japanese Subjects with Chronic Lymphocytic Leukemia

Kiyohiko Hatake, MD PhD, Kazuhito Yamamoto, MDPhD, Noriko Fukuhara, MD PhD, Shigeru Kusumoto, MD, Koji Izutsu, MD, PhD, Ilseung Choi, MD, Hirokazu Nagai, MD PhD, Hideyuki Honda, BS, Junjiro Saeki, MS, Andrew W. Roberts, MS, Paulo Maciag, MD PhD, Suresh Agarwal, MS, PhD RPh, Ahmed Hamed Salem, PhD, Kevin J. Freise, PhD, Tsukasa Kiriyama, PharmD, BSc, Kensei Tobinai, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5352.
https://doi.org/10.1182/blood.V130.Suppl_1.5352.5352
Published: 2017
Journal Articles

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Clinical Trials & Observations
Harriet S. Walter, Simon A. Rule, Martin J. S. Dyer, Lionel Karlin, Ceri Jones, Bruno Cazin, Philippe Quittet, Nimish Shah, Claire V. Hutchinson, Hideyuki Honda, Kevin Duffy, Joseph Birkett, Virginia Jamieson, Nigel Courtenay-Luck, Toshio Yoshizawa, John Sharpe, Tomoya Ohno, Shinichiro Abe, Akihisa Nishimura, Guillaume Cartron, Franck Morschhauser, Christopher Fegan, Gilles Salles
Journal: Blood
Blood (2016) 127 (4): 411–419.
https://doi.org/10.1182/blood-2015-08-664086
Published: 2016
Includes: Supplemental data
Journal Articles

ONO-4059—a Potent and Selective Reversible Bruton’s Tyrosine Kinase (Btk) Inhibitor: Single Agent, Twice Daily (BD) Dosing and Dosing with Food Results in Sustained, High Trough Levels of ONO-4059, Translating into 100% Tumour Remission in a TMD-8 Xenograft Model

Toshio Yoshizawa, Tomoko Yasuhiro, Hideyuki Honda, Kazuhito Kawabata, PhD
Journal: Blood
Blood (2014) 124 (21): 4502.
https://doi.org/10.1182/blood.V124.21.4502.4502
Published: 2014
Journal Articles

The Bruton’s Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL)

Christopher Fegan, Joanne Bagshawe, Gilles Salles, MDPhD, Lionel Karlin, Simon Rule, Nimish Shah, Franck Morschhauser, Louis Terriou, Martin JS Dyer, Harriet Walter, Claire Hutchinson, Guillaume Cartron, MD, John Sharpe, Kevin Duffy, Akhisa Nishimura, Shin-ichiro Abe, Hideyuki Honda, Tomoko Yasuhiro, Toshio Yoshizawa, Joseph Birkett, Nigel Courtenay-Luck
Journal: Blood
Blood (2014) 124 (21): 3328.
https://doi.org/10.1182/blood.V124.21.3328.3328
Published: 2014
Journal Articles

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma

Simon Rule, MD, Nimish Shah, MD, Gilles Andre Salles, MD, PhD, Lionel Karlin, MD, Franck Morschhauser, MD, PhD, Louis Terriou, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Claire Hutchinson, BMedSci, MRCP, FRCPath, Chris Fegan, MBBS, Guillaume Cartron, MD, PhD, Tomasz Knurowski, MD, James G Wright, PhD, Andrew J Saunders, MD, Hideyuki Honda, Bsc, Andrew Mazur, Toshio Yoshizawa, PhD, Kazuhito Kawabata, PhD, Joseph TP Birkett, PhD
Journal: Blood
Blood (2013) 122 (21): 4397.
https://doi.org/10.1182/blood.V122.21.4397.4397
Published: 2013
Journal Articles

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory and High Risk Chronic Lymphocytic Leukaemia (CLL)

Gilles Andre Salles, MD, PhD, Lionel Karlin, MD, Simon Rule, MD, Nimish Shah, MD, Franck Morschhauser, MD, PhD, Louis Terriou, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Claire Hutchinson, BMedSci, MRCP, FRCPath, Chris Fegan, MBBS, Guillaume Cartron, MD, PhD, Tomasz Knurowski, MD, Andrew J Saunders, MD, James G Wright, PhD, Hideyuki Honda, Bsc, Andrew Mazur, Toshio Yoshizawa, PhD, Kazuhito Kawabata, PhD, Joseph TP Birkett, PhD
Journal: Blood
Blood (2013) 122 (21): 676.
https://doi.org/10.1182/blood.V122.21.676.676
Published: 2013